Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386986970> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4386986970 endingPage "763" @default.
- W4386986970 startingPage "794" @default.
- W4386986970 abstract "Paclitaxel is a widely used cancer chemotherapeutic agent for many solid tumors; but peripheral neuropathy is a major limitation for its clinical use. Studies have demonstrated the usefulness of flavone derivatives in chemotherapy induced peripheral neuropathy. The present study evaluates the anti-neuropathic effect of 3′, 4′-dihydroxyflavone on paclitaxel-induced peripheral neuropathy and the underlying mechanisms. Paclitaxel was administered to mice in a single dose of 10 mg/kg, i.p.The neuropathic behavioural parameters such as mechanical allodynia, cold allodynia and thermal hyperalgesia were assessed 24 h later. The test compound 3′, 4′-dihydroxyflavone (50,100 or 200 mg/kg,s.c) was administered 30 min prior to the assessment of behavioral parameters. The possible mechanisms involving KATP channels, adenosine and GABAA receptors were explored by employing suitable interacting drugs. Molecular docking studies to predict the binding interactions of 3′, 4′-dihydroxyflavone at the above targets were also carried out. The test compound 3′, 4′-dihydroxyflavoneexhibited a significant reduction in paw withdrawal response score in both mechanical and cold allodynia and also increased the tail flick response time in thermal hyperalgesia due to paclitaxel-induced neuropathy. The anti-neuropathic effect of 3′, 4′-dihydroxyflavonewas significantly reversed by pre-treatment with glibenclamide, caffeine or bicuculline revealing the involvement of KATP channels, adenosine and GABAA receptors respectively. Furthermore, the molecular docking studies indicated a favourable binding affinity and good H-bond interaction of 3′, 4′-dihydroxyflavone at these targets. The findings of the present study suggests that, 3′, 4′-dihydroxyflavone has anti-neuropathic effect against paclitaxel-induced peripheral neuropathy through mechanisms that involve KATP channels, adenosine (A3) and GABAA (α2 subunit) receptors." @default.
- W4386986970 created "2023-09-24" @default.
- W4386986970 creator A5082392201 @default.
- W4386986970 date "2023-06-30" @default.
- W4386986970 modified "2023-10-18" @default.
- W4386986970 title "3′, 4′-dihydroxyflavone ameliorates paclitaxel model of peripheral neuropathy in mice by modulating KATP channel, adenosine (A3) and GABAA (a2 subunit) receptors" @default.
- W4386986970 doi "https://doi.org/10.6026/97320630019754" @default.
- W4386986970 hasPublicationYear "2023" @default.
- W4386986970 type Work @default.
- W4386986970 citedByCount "0" @default.
- W4386986970 crossrefType "journal-article" @default.
- W4386986970 hasAuthorship W4386986970A5082392201 @default.
- W4386986970 hasBestOaLocation W43869869701 @default.
- W4386986970 hasConcept C126322002 @default.
- W4386986970 hasConcept C134018914 @default.
- W4386986970 hasConcept C15490471 @default.
- W4386986970 hasConcept C168258287 @default.
- W4386986970 hasConcept C170493617 @default.
- W4386986970 hasConcept C2776694085 @default.
- W4386986970 hasConcept C2776991684 @default.
- W4386986970 hasConcept C2777107010 @default.
- W4386986970 hasConcept C2777292972 @default.
- W4386986970 hasConcept C2777883359 @default.
- W4386986970 hasConcept C2778938600 @default.
- W4386986970 hasConcept C2779245659 @default.
- W4386986970 hasConcept C2779901536 @default.
- W4386986970 hasConcept C555293320 @default.
- W4386986970 hasConcept C67907053 @default.
- W4386986970 hasConcept C71924100 @default.
- W4386986970 hasConcept C98274493 @default.
- W4386986970 hasConceptScore W4386986970C126322002 @default.
- W4386986970 hasConceptScore W4386986970C134018914 @default.
- W4386986970 hasConceptScore W4386986970C15490471 @default.
- W4386986970 hasConceptScore W4386986970C168258287 @default.
- W4386986970 hasConceptScore W4386986970C170493617 @default.
- W4386986970 hasConceptScore W4386986970C2776694085 @default.
- W4386986970 hasConceptScore W4386986970C2776991684 @default.
- W4386986970 hasConceptScore W4386986970C2777107010 @default.
- W4386986970 hasConceptScore W4386986970C2777292972 @default.
- W4386986970 hasConceptScore W4386986970C2777883359 @default.
- W4386986970 hasConceptScore W4386986970C2778938600 @default.
- W4386986970 hasConceptScore W4386986970C2779245659 @default.
- W4386986970 hasConceptScore W4386986970C2779901536 @default.
- W4386986970 hasConceptScore W4386986970C555293320 @default.
- W4386986970 hasConceptScore W4386986970C67907053 @default.
- W4386986970 hasConceptScore W4386986970C71924100 @default.
- W4386986970 hasConceptScore W4386986970C98274493 @default.
- W4386986970 hasIssue "6" @default.
- W4386986970 hasLocation W43869869701 @default.
- W4386986970 hasOpenAccess W4386986970 @default.
- W4386986970 hasPrimaryLocation W43869869701 @default.
- W4386986970 hasRelatedWork W1579347021 @default.
- W4386986970 hasRelatedWork W2050395463 @default.
- W4386986970 hasRelatedWork W2055963899 @default.
- W4386986970 hasRelatedWork W2087295337 @default.
- W4386986970 hasRelatedWork W3023978917 @default.
- W4386986970 hasRelatedWork W3025055414 @default.
- W4386986970 hasRelatedWork W4296499271 @default.
- W4386986970 hasRelatedWork W4311219729 @default.
- W4386986970 hasRelatedWork W4313584630 @default.
- W4386986970 hasRelatedWork W2782654094 @default.
- W4386986970 hasVolume "19" @default.
- W4386986970 isParatext "false" @default.
- W4386986970 isRetracted "false" @default.
- W4386986970 workType "article" @default.